Journal of Clinical Oncology
Articles in this Issue
Advancing treatment of low-grade upper tract urothelial carcinoma (LG UTUC) with padeliporfin vascular-targeted photodynamic therapy (VTP): The ENLIGHTED phase 3 trial.
TPS4643 Background: Padeliporfin VTP is a drug-led combination therapy consisting of IV Padeliporfin activated by a low-po...
Clinicogenomic characteristics associated with non-durable response to first-line immunotherapy among advanced lung squamous cell carcinoma with PD-L1 ≥ 50%.
e20614 Background: While immune checkpoint inhibitors (ICIs) are a cornerstone of therapy in advanced lung squamous cell c...
Botensilimab (BOT) ± balstilimab (BAL) in patients (pts) with advanced cutaneous melanoma (cMEL) refractory/resistant (R/R) to anti–PD-(L)1 ± CTLA-4: A phase 2 trial.
9543 Background: Pts with advanced cMEL R/R to PD-(L)1–based therapy, including PD-(L)1+CTLA-4, have few treatment options...
Neoadjuvant therapy for head and neck squamous cell carcinoma based on hyperprogression genotyping: Cetuximab beta combined with chemotherapy with or without camrelizumab.
TPS6139 Background: Surgery remains the preferred treatment option for locally advanced head and neck squamous cell carcin...
Differential detection of BRCA-associated cancer risk and Lynch syndrome in genomic screening.
e13537 Background: Hereditary cancer syndromes such as BRCA-associated hereditary breast and ovarian cancer (HBOC) and Lyn...
Characterization of germline pathogenic variants in melanoma patients.
9590 Background: Approximately 10% of melanomas arise from hereditary predisposition. NCCN guidelines recommend genetic co...
Nivolumab plus temozolomide (Nivo/Tem) vs. temozolomide monotherapy in refractory melanoma.
e21507 Background: While immunotherapy (IT) is first-line therapy for advanced melanoma, many patients are refractory, nec...
Bone marrow immune cell state analysis and selective APC alterations in prolonged cytopenia following CAR T-cell therapy.
e19018 Background: Prolonged cytopenia (PSC) following chimeric antigen receptor (CAR) T-cell therapy is common and associ...
Using large language models to extract diagnosis, recurrence, and death dates from breast cancer electronic medical records.
e13005 Background: Breast cancer research needs accurate extraction of clinical event dates (e.g., recurrence dates) from...
Guideline adherence in action: Baseline neuroimaging rates for NSCLC—A Northern Ireland North West Cancer Centre single-institution experience.
e20653 Background: Brain metastases are common in patients with Non-Small Cell Cancer (NSCLC) and significantly impact tre...
Verification of clinical benefit following FDA accelerated approval in oncology: A time-to-event analysis.
e23041 Background: The FDA Accelerated Approval (AA) program enables earlier access to therapies for patients with serious...
Efficacy of YES, an mHealth intervention for adolescent and young adults (AYA) with breast cancer (BC), to address AYA survivorship concerns.
12009 Background: AYA BC survivors often have unmet concerns that are understudied and sub-optimally addressed. Primary re...
Prognostic factors in malignant thymic neoplasms: A comprehensive real-world analysis from a Brazilian tertiary center.
e20174 Background: Malignant thymic neoplasms are rare and biologically heterogeneous tumors, with limited prospective dat...
Updated efficacy of dalpiciclib and nonsteroidal aromatase inhibitors (NSAIs) in estrogen receptor–positive (ER+) recurrent/metastatic (R/M) ovarian cancer and uterine neoplasms.
5559 Background: Initial results from our trial showed the anti-tumor activity and good tolerance of CDK4/6 inhibitor dalp...
Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.
e14535 Background: Anti-programmed cell death ligand PD-L1/PD-1 immune checkpoint inhibitors (ICIs) are approved for metas...
Real-world outcomes of reiki as an integrative supportive care intervention at a comprehensive cancer center in the MENA region.
e24081 Background: Integrative medicine interventions, including Reiki, are increasingly incorporated into oncology suppor...
Anti-tumor activity of FF-10850 (liposomal topotecan) in patients with advanced Merkel cell carcinoma.
9581 Background: FF-10850 is a novel liposomal topotecan with increased intratumoral accumulation and robust pre-clinical...
Preliminary results of pegylated liposomal doxorubicin, dacarbazine, and toripalimab in patients with advanced primary cardiac sarcoma: An interim analysis.
11575 Background: Primary cardiac sarcoma (PCS) is an ultra-rare malignancy with a dismal prognosis, with previously repor...
Interstitial lung disease as a predictor of inpatient outcomes among patients with breast cancer.
e12734 Background: Interstitial lung disease (ILD) is an important comorbidity among patients with breast cancer, influenc...
Association of β-blocker selectivity with survival and immune-related outcomes in melanoma and lung cancer patients treated with immune checkpoint inhibitors.
11152 Background: Immune checkpoint inhibitors (ICIs) are standard of care for advanced melanoma and lung cancer. Retrospe...
Localized (Z)- <i>n</i> -butylidenephthalide biodegradable wafer as surgical adjuvant in recurrent glioblastoma for extending survival and re-sensitizing chemotherapy: A compassionate use study.
e14089 Background: Surgical resection of recurrent glioblastoma is often limited by anatomical constraints and neurologica...
Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM).
7528 Background: Lenalidomide (Len) maintenance after ASCT has been a standard of care for patients (pts) with MM. Histori...
Comparative incidence of infections and cytopenias in BCMA- vs GPRC5D-targeting bispecific antibodies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions.
e19505 Background: Bispecific antibodies (BsAbs) targeting BCMA and GPRC5D have demonstrated substantial efficacy in relap...
Global burden of lung cancer from 2000 to 2023 and projections to 2035: Implications for ctDNA-based molecular residual disease–guided care.
e22519 Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with non-small...
Effectiveness and safety of transarterial chemoembolization combined with apatinib in hepatocellular carcinoma: A systematic review and proportional meta-analysis.
e16199 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-re...